Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia

Netherlands Journal of Medicine

Volumn 66, Issue 1, 2008, Pages 27-30

  Korte, M R ^a   van Heerde, M J ^a   de Man, R A ^a   Betjes, M H G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cryoglobulinaemia; Glomerulonephritis; Hepatitis C; Liver transplantation; Rituximab

Indexed keywords

CORTICOSTEROID; CRYOGLOBULIN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; LAMIVUDINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PREDNISONE; RIBAVIRIN; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; CASE REPORT; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LEG EDEMA; LIVER TRANSPLANTATION; LYMPHOCYTE DEPLETION; MALE; NEPHROTOXICITY; PHYSICAL EXAMINATION; PLASMAPHERESIS; VASCULITIS;

ANTIBODIES, MONOCLONAL; CRYOGLOBULINEMIA; GLOMERULONEPHRITIS; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED;

EID: 38849185988     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Coca P, Costadoat-Chalumeau N, Liclove O, Aric L. Cryoglobulinaemia vasculitis. Curr Opion Rheumatol 2002;14:29-35.
2. De Vita S, De Re V, Gasparotto D, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinaemia. Arthritis Rheum 2000;34:94-102.
3. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinaemia. N Engl J Med 1992;327:1490-5.
4. Rocatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonefritis. Am J Kidney Dis 2007;49:69-82.
5. Quartuccio L, Soardo G, Romano, et al. Rituximab treatment for glomerulonefritis in HCV-associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatology 2006;45:842-6.
6. Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hemat Oncol Clin North America 1999;13:1315-49.
7. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinaemia. Medicine 2002;81:398-409.
8. Kamar N, Rostaing L, Alric C. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006;69:436-9.
9. Bruchfield A, Saadoun D, Cacoub P. Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia - anti-viral therapy vs rituxmab. Rheumatology 2006;45:783-84.
10. Neumann U, Puhl G, Bahra M, et al. Treatment of Patients with Recurrent Hepatitis C after Liver Transplantation with Peginterferon Alfa-2B Plus Ribavirin. Transplantaion 2006;82:43-7.
11. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis. Am J Transplant 2006;6:1586-99.
12. Davis CL, Gretch DR, Perkins JD, et al. Hepatitis C-associated glomerular disease in liver transplant recipients. Liver Transpl Surg 1995;1:166-75.
13. Pham HP, Feray C, Samuel D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant patients. Kidney Int 1998;54:1311-9.
14. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995;22:1084-9.
15. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinaemia. Blood 2003;101:3827-34.
16. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinaemia resistant to interferon alfa with an anti-CD20. Blood 2003;101:3818-26.
17. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonefiritis. Nephrol Dial Transplant 2004;19:3054-61.
18. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (Rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinmemia with renal and cardiac failure. Am J Kidney Dis 2004;43:E34-8.
19. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (Rituximab). Ann Rheum DiS 2002;61:922-4.
20. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20.
21. Bestard O, Cruzado JM, Ercilla, G, et al. Rituximab induces regression of hepatitis C virus-related membrane proliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant 2006;21:2320-4.
22. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase 11 study. Blood 1998;92:1927-32.
23. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000;96:1184-6.
24. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-9.
25. Noy A. Update in HIV lymphoma. Curr Opin Cncol 2006;18:449-55.
26. Basse G, Ribes D, Kamar N, et al. Rituximab therapy for mixed cryoglobulinaemia in seven renal transplant patients. Transplant Proc 2006,38:2308-10.